First-half medtech acquisition value surpasses 2013 total (EP Vantage)
Source
EP Vantage
Company
Thermo Fisher Scientific, Abbott Laboratories, Ansell, Bausch + Lomb, Baxter International, Bayer, bioMérieux, Cardinal Health, CareFusion, Covidien, Essilor International, Grifols, Illumina, Johnson & Johnson, Kinetic Concepts, Medtronic, MicroPort Scientific, Novartis, Smith & Nephew, Stryker, Valeant Pharmaceuticals International
Tags
Analysis, Company Strategy, Medtech, Subsidiary, Disposal, Acquisition, Merger, Free Content
Date
July 22, 2014
Large medtech companies seem to have found some loose change down the back of the sofa. At the half-year point the combined value of acquisitions closed in the device space has reached $26.8bn, already greater than the total for all of 2013.
This is all the more remarkable because it does not include the still-open megadeals contracted in the second quarter by Medtronic and Zimmer. Although only 82 medtech M&A transactions have been concluded in the first half, fewer than the 98 seen a year earlier, acquirers are picking their targets carefully, and when they find what they want they are willing to spend substantial a...
